GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Piotroski F-Score

Fortress Biotech (Fortress Biotech) Piotroski F-Score : 3 (As of Apr. 27, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Fortress Biotech has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Fortress Biotech's Piotroski F-Score or its related term are showing as below:

FBIO' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 3

During the past 13 years, the highest Piotroski F-Score of Fortress Biotech was 4. The lowest was 1. And the median was 3.


Fortress Biotech Piotroski F-Score Historical Data

The historical data trend for Fortress Biotech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Piotroski F-Score Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 3.00 1.00 3.00

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 - 1.00 3.00 3.00

Competitive Comparison of Fortress Biotech's Piotroski F-Score

For the Biotechnology subindustry, Fortress Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -21.537 + -24.776 + -5.045 + -9.279 = $-60.64 Mil.
Cash Flow from Operations was -43.22 + -33.291 + -16.779 + -34.935 = $-128.23 Mil.
Revenue was 12.429 + 17.386 + 34.752 + 19.946 = $84.51 Mil.
Gross Profit was 5.98 + 9.619 + 28.323 + 13.931 = $57.85 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(294.301 + 263.551 + 180.719 + 150.549 + 167.526) / 5 = $211.3292 Mil.
Total Assets at the begining of this year (Dec22) was $294.30 Mil.
Long-Term Debt & Capital Lease Obligation was $79.14 Mil.
Total Current Assets was $117.02 Mil.
Total Current Liabilities was $84.91 Mil.
Net Income was -15.76 + -21.356 + -22.511 + -26.948 = $-86.58 Mil.

Revenue was 23.925 + 18.886 + 16.528 + 16.404 = $75.74 Mil.
Gross Profit was 15.722 + 11.253 + 9.307 + 8.686 = $44.97 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(396.503 + 407.93 + 363.955 + 323.561 + 294.301) / 5 = $357.25 Mil.
Total Assets at the begining of last year (Dec21) was $396.50 Mil.
Long-Term Debt & Capital Lease Obligation was $114.71 Mil.
Total Current Assets was $230.43 Mil.
Total Current Liabilities was $127.72 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Fortress Biotech's current Net Income (TTM) was -60.64. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Fortress Biotech's current Cash Flow from Operations (TTM) was -128.23. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-60.637/294.301
=-0.20603736

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-86.575/396.503
=-0.21834639

Fortress Biotech's return on assets of this year was -0.20603736. Fortress Biotech's return on assets of last year was -0.21834639. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Fortress Biotech's current Net Income (TTM) was -60.64. Fortress Biotech's current Cash Flow from Operations (TTM) was -128.23. ==> -128.23 <= -60.64 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=79.138/211.3292
=0.37447736

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=114.714/357.25
=0.32110287

Fortress Biotech's gearing of this year was 0.37447736. Fortress Biotech's gearing of last year was 0.32110287. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=117.022/84.908
=1.37822113

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=230.432/127.715
=1.80426731

Fortress Biotech's current ratio of this year was 1.37822113. Fortress Biotech's current ratio of last year was 1.80426731. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Fortress Biotech's number of shares in issue this year was 10.761. Fortress Biotech's number of shares in issue last year was 6.05. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=57.853/84.513
=0.68454557

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=44.968/75.743
=0.59369183

Fortress Biotech's gross margin of this year was 0.68454557. Fortress Biotech's gross margin of last year was 0.59369183. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=84.513/294.301
=0.28716518

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=75.743/396.503
=0.19102756

Fortress Biotech's asset turnover of this year was 0.28716518. Fortress Biotech's asset turnover of last year was 0.19102756. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Fortress Biotech has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Fortress Biotech  (NAS:FBIO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Fortress Biotech Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (Fortress Biotech) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Executives
Rosenwald Lindsay A Md director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN 375 PARK AVE, NEW YORK NY 10152
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin officer: Chief Financial Officer C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein director C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter officer: Chief Financial Officer 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein director 750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN 750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey director 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz director C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos officer: SVP, Biologics Operations C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan other: Former Chief Medical Officer C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett director ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803

Fortress Biotech (Fortress Biotech) Headlines

From GuruFocus

Fortress Biotech Announces Reverse Stock Split

By Marketwired 10-09-2023

Fortress Biotech Appoints David Jin as Chief Financial Officer

By PurpleRose PurpleRose 07-22-2022